ZA946176B - The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases - Google Patents
The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseasesInfo
- Publication number
- ZA946176B ZA946176B ZA946176A ZA946176A ZA946176B ZA 946176 B ZA946176 B ZA 946176B ZA 946176 A ZA946176 A ZA 946176A ZA 946176 A ZA946176 A ZA 946176A ZA 946176 B ZA946176 B ZA 946176B
- Authority
- ZA
- South Africa
- Prior art keywords
- pct
- flupirtine
- primary
- neurodegenerative diseases
- neuroprotective effect
- Prior art date
Links
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003667 flupirtine Drugs 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title 1
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 231100001018 bone marrow damage Toxicity 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 231100000874 brain damage Toxicity 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Confectionery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4327516A DE4327516A1 (de) | 1993-08-17 | 1993-08-17 | Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA946176B true ZA946176B (en) | 1995-03-20 |
Family
ID=6495312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA946176A ZA946176B (en) | 1993-08-17 | 1994-08-16 | The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases |
Country Status (27)
Country | Link |
---|---|
US (1) | US5721258A (fr) |
EP (1) | EP0716602B1 (fr) |
JP (1) | JPH09501664A (fr) |
KR (1) | KR100341952B1 (fr) |
CN (1) | CN1086291C (fr) |
AT (1) | ATE210442T1 (fr) |
AU (1) | AU694447B2 (fr) |
BG (1) | BG62430B1 (fr) |
BR (1) | BR9407293A (fr) |
CA (1) | CA2169718C (fr) |
CZ (1) | CZ289040B6 (fr) |
DE (2) | DE4327516A1 (fr) |
DK (1) | DK0716602T3 (fr) |
EE (1) | EE03204B1 (fr) |
ES (1) | ES2168309T3 (fr) |
HR (1) | HRP940464A2 (fr) |
HU (1) | HU227765B1 (fr) |
IL (1) | IL110681A (fr) |
NO (1) | NO309842B1 (fr) |
NZ (1) | NZ273292A (fr) |
PT (1) | PT716602E (fr) |
RU (1) | RU2166318C2 (fr) |
SK (1) | SK283330B6 (fr) |
UA (1) | UA43351C2 (fr) |
WO (1) | WO1995005175A1 (fr) |
YU (1) | YU49215B (fr) |
ZA (1) | ZA946176B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539861A1 (de) * | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
DE19541405A1 (de) * | 1995-11-07 | 1997-05-15 | Asta Medica Ag | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen |
DE19625582A1 (de) * | 1996-06-27 | 1998-01-02 | Asta Medica Ag | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen |
ES2235368T3 (es) * | 1997-10-27 | 2005-07-01 | Sumitomo Pharmaceuticals Company, Limited | Derivados de amida para tratar alteraciones neurodegenerativas de la retina. |
AU1359801A (en) * | 1999-11-05 | 2001-06-06 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
US6821995B1 (en) | 1999-12-01 | 2004-11-23 | Duke University | Method of treating batten disease |
AU1353901A (en) * | 1999-12-01 | 2001-06-12 | Duke University | Method of treating batten disease |
DE10327674A1 (de) | 2003-06-20 | 2005-01-05 | Awd.Pharma Gmbh & Co. Kg | Injizierbare Darreichungsform von Flupirtin |
DE10328260A1 (de) * | 2003-06-23 | 2005-01-27 | Schmidt, K.-G., Dr. med. | Flupirtine-Präparat |
CN1917876A (zh) * | 2003-12-16 | 2007-02-21 | Cns生物有限公司 | 方法和组合物 |
WO2006065204A1 (fr) * | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Aminopyridines substituees et utilisations |
EP1688141A1 (fr) | 2005-01-31 | 2006-08-09 | elbion AG | Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable |
US20060258708A1 (en) * | 2005-05-16 | 2006-11-16 | Andrulis Peter J Jr | Method for treating Parkinson's disease and other neurological diseases |
US20080279930A1 (en) * | 2007-05-07 | 2008-11-13 | Bernd Terhaag | Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof |
DE102011006425A1 (de) | 2010-03-31 | 2011-10-06 | Awd.Pharma Gmbh & Co. Kg | Pharmazeutische Zubereitung und deren Verwendung |
DE102010030053A1 (de) | 2010-06-14 | 2011-12-15 | Awd.Pharma Gmbh & Co.Kg | Injizierbare Darreichungsform von Flupirtin |
EP3027188A4 (fr) * | 2013-07-31 | 2017-03-01 | Teva Pharmaceutical Industries Ltd. | Traitement de la sclérose en plaques par combinaison de laquinimode et de flupirtine |
WO2019014547A1 (fr) * | 2017-07-14 | 2019-01-17 | Texas Tech University System | Carbamates de pyridine fonctionnalisés présentant une activité neuroprotectrice améliorée |
DE102017007385A1 (de) | 2017-08-02 | 2019-02-07 | Christoph Hoock | Maleatfreie feste Arzneimittelformen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481205A (en) * | 1980-09-13 | 1984-11-06 | Degussa Aktiengesellschaft | 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate |
DE3369315D1 (en) * | 1982-10-27 | 1987-02-26 | Degussa | Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity |
DE3337593A1 (de) * | 1982-10-27 | 1984-05-03 | Degussa Ag, 6000 Frankfurt | 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung |
NO860825L (no) * | 1985-03-23 | 1986-09-24 | Degussa | Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin. |
IN172468B (fr) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag |
-
1993
- 1993-08-17 DE DE4327516A patent/DE4327516A1/de not_active Ceased
-
1994
- 1994-08-10 EP EP94926828A patent/EP0716602B1/fr not_active Expired - Lifetime
- 1994-08-10 DK DK94926828T patent/DK0716602T3/da active
- 1994-08-10 HU HU9600355A patent/HU227765B1/hu unknown
- 1994-08-10 WO PCT/EP1994/002649 patent/WO1995005175A1/fr active IP Right Grant
- 1994-08-10 ES ES94926828T patent/ES2168309T3/es not_active Expired - Lifetime
- 1994-08-10 SK SK214-96A patent/SK283330B6/sk not_active IP Right Cessation
- 1994-08-10 PT PT94926828T patent/PT716602E/pt unknown
- 1994-08-10 RU RU96105707/14A patent/RU2166318C2/ru active
- 1994-08-10 AU AU76528/94A patent/AU694447B2/en not_active Expired
- 1994-08-10 KR KR1019960700753A patent/KR100341952B1/ko active IP Right Grant
- 1994-08-10 DE DE69429435T patent/DE69429435T2/de not_active Expired - Lifetime
- 1994-08-10 BR BR9407293A patent/BR9407293A/pt not_active Application Discontinuation
- 1994-08-10 NZ NZ273292A patent/NZ273292A/en not_active IP Right Cessation
- 1994-08-10 CN CN94193106A patent/CN1086291C/zh not_active Expired - Lifetime
- 1994-08-10 AT AT94926828T patent/ATE210442T1/de active
- 1994-08-10 JP JP7506731A patent/JPH09501664A/ja active Pending
- 1994-08-10 CA CA002169718A patent/CA2169718C/fr not_active Expired - Lifetime
- 1994-08-10 CZ CZ1996465A patent/CZ289040B6/cs not_active IP Right Cessation
- 1994-08-10 US US08/602,742 patent/US5721258A/en not_active Expired - Lifetime
- 1994-08-15 YU YU51294A patent/YU49215B/sh unknown
- 1994-08-16 ZA ZA946176A patent/ZA946176B/xx unknown
- 1994-08-16 IL IL11068194A patent/IL110681A/xx not_active IP Right Cessation
- 1994-08-16 HR HRP4327516.8A patent/HRP940464A2/hr not_active Application Discontinuation
- 1994-10-08 UA UA96030972A patent/UA43351C2/uk unknown
- 1994-10-25 EE EE9400160A patent/EE03204B1/xx unknown
-
1996
- 1996-02-14 BG BG100356A patent/BG62430B1/bg unknown
- 1996-02-15 NO NO960607A patent/NO309842B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9600355D0 (en) | The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases | |
HUT71814A (en) | Process for producing pharmaceutical compositions for the treatment of neurological lesions related to traumatic injuries | |
HU9501953D0 (en) | Pharmaceutically active pyridine derivatives and process for the preparation thereof | |
PT703786E (pt) | Utilizacao de nonapeptideos e decapeptideos para a preparacao de um medicamento para o tratamento da sida | |
ZA965235B (en) | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders | |
NZ271363A (en) | Use of antiglucocorticoid steroids to treat anxiety disorders | |
HUT68007A (en) | Pharmaceutical compositions for preventing and treating retinal diseases and process for preparing them | |
PL312983A1 (en) | Therapeutic preparation | |
HUT77868A (hu) | Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra | |
AU6569794A (en) | Medicaments for treatment of migraine, epilepsy and feeding disorders | |
AU4687501A (en) | Medicine for treating traumatic brain injury and other neuronal disorders | |
NZ268914A (en) | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease | |
HU9802142D0 (en) | Use of na+/h+ -ion-exchange inhibitors for producing pharmaceutical compositions for treating and profilacting diseases of the central nerve system | |
AU5768298A (en) | Use of benzoylalkyl-1,2,3,6-tetrahydropyridins | |
ZA925983B (en) | Pharmaceutical compositions for the treatment of skin disorders |